Skye Bioscience Inc (SKYE)

[AntonChigurh]

Were at 40M fully diluted

and if the financing goes through (Series D) it will mean another 60m shares of common stock if fully converted.

So, not triple. And while that is significant dilution, the EV of the company doesn't change immediately (market cap - cash) and given the position Nemus has worked to get itself in, that Cash will be used to show the efficacy of Two of their drugs in clinical trials. These trials will go Well because Nemus has done their homework.

If your a Long, that means a significant re-rate of the stock price (which is a metric for how much the market values the pipeline) Even with the dilution.

Look at Zynerba, swing and a Miss on their lead candidate but Market Cap - Cash still values the Pipeline at around 20m. That is with a candidate apparently entering Phase 3 after failing Phase 2 trials, and a pre-clinical drug.

I think the score will be much different in a year.

PS = even with the Series D financing, Nemus will have = or less shares outstanding than $CNBX $IMLFF $OWCP which all have bigger market caps than Nemus right now. They have done all their financing's diligently thus far.